China Nuokang Bio - Pharmaceutical (NKBP)
China Nuokang Bio - Pharmaceutical Revenues: 9.059M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
NKBP Revenues Rankings
| Overall | 12th percentile | 3878 of 4432 |
| Sector | 31st percentile | 323 of 470 in Healthcare |
| Industry | 48th percentile | 68 of 132 in Biotechnology |
NKBP Revenues Range, Past 5 Years
| Minimum | 8.725M | Mar 2009 |
| Maximum | 33.02M | Sep 2009 |
| Average | 12.87M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these NKBP related companies
NKBP News
China Nuokang Bio-Pharmaceutical Inc. Reports First Quarter 2012 Financial Results
May 23, 4:01PM GlobeNewswire
May 23, 4:01PM GlobeNewswire
China Nuokang Bio-Pharma (NKBP) Forms Committee for 'Go Private' Proposal
May 21, 8:04AM Street Insider
May 21, 8:04AM Street Insider
China Nuokang Bio-Pharmaceutical Inc. to Report First Quarter 2012 Financial Results
May 10, 9:00AM GlobeNewswire
May 10, 9:00AM GlobeNewswire
Unusual 11 Mid-Day Movers 05/09: (SODA) (NKBP) (HTH) Higher; (MEMS) (CQB) (AMRS) Lower
May 09, 2:25PM Street Insider
May 09, 2:25PM Street Insider
China Nuokang Bio-Pharma (NKBP) Receives 'Go Private' Bid from Chairman Xue for $5.80/ADS
May 09, 7:04AM Street Insider
May 09, 7:04AM Street Insider
China Nuokang Bio-Pharmaceutical Inc. Announces Receipt of "Going Private" Proposal
May 09, 7:00AM GlobeNewswire
May 09, 7:00AM GlobeNewswire
$NKBP does not provide clear insight on the company's ability to increase earnings
about 24 days ago by sentinelforNKBP
about 24 days ago by sentinelforNKBP
$NKBP is a micro-cap with high risk: strong sell. For NKBP no development and growth http://chart.ly/mdvspdx
about 51 days ago by againstfalsetrade
about 51 days ago by againstfalsetrade
China Nuokang Bio-Pharmaceutical Inc. Reports Fourth Quarter and Full Year 2011 Financial Results
Mar 14, 4:01PM GlobeNewswire
Mar 14, 4:01PM GlobeNewswire
$NKBP isn' a money-making for shareholders...who gains by its fell? http://chart.ly/3mijscc
about 90 days ago by sentinelforNKBP
about 90 days ago by sentinelforNKBP
$ NKBP this company can't produce profits $NKBP http://chart.ly/d2uobf2
about 90 days ago by sentinelforNKBP
about 90 days ago by sentinelforNKBP
$NKBP (NASDAQ) since its IPO 2009 NKBP didn't produce profits. From 2009 to 2012 NKBP show a negative return on equity
about 90 days ago by sentinelforNKBP
about 90 days ago by sentinelforNKBP
China Nuokang (NKBP) Makes Several Management Changes; Sees 'Substantial' Drop in FY11 Net Income
Feb 27, 9:09AM Street Insider
Feb 27, 9:09AM Street Insider
China Nuokang Bio-Pharmaceutical Provides Update on Continued Restructuring Efforts
Feb 27, 9:04AM Benzinga
Feb 27, 9:04AM Benzinga
China Nuokang Bio-Pharmaceutical Inc. to Report Fourth Quarter and Full Year 2011 Financial Results
Feb 27, 9:01AM GlobeNewswire
Feb 27, 9:01AM GlobeNewswire
China Nuokang Bio-Pharmaceutical Inc. Provides Update on Continued Restructuring Efforts
Feb 27, 9:00AM GlobeNewswire
Feb 27, 9:00AM GlobeNewswire
China Nuokang Bio-Pharmaceutical Acquires Alpha Lipoic Acid Capsule for Diabetic Patients
Jan 11, 9:01AM Benzinga
Jan 11, 9:01AM Benzinga
China Nuokang Bio-Pharmaceutical Inc. Announces Results of 2011 Annual General Meeting
Dec 23, 4:00PM GlobeNewswire
Dec 23, 4:00PM GlobeNewswire
China Nuokang Bio-Pharmaceutical Inc. Appoints David Gao to Board of Directors
Dec 20, 9:00AM GlobeNewswire
Dec 20, 9:00AM GlobeNewswire
China Nuokang Bio-Pharmaceutical Inc. Announces Date of Annual General Meeting
Nov 22, 9:00AM GlobeNewswire
Nov 22, 9:00AM GlobeNewswire
China Nuokang Bio-Pharmaceutical Inc. Reports Third Quarter 2011 Financial Results
Nov 17, 4:01PM GlobeNewswire
Nov 17, 4:01PM GlobeNewswire
China Nuokang Bio-Pharmaceutical Inc. to Present at Cowen's China Opportunity Conference
Nov 07, 9:00AM GlobeNewswire
Nov 07, 9:00AM GlobeNewswire
$NKBP
China Noukang Bio-Pharmaceutical Reports Q2 EPS $0.11 vs $0.08 Est; Revenues $12.3M vs $10.0M Est
about 279 days ago by Benzinga
about 279 days ago by Benzinga
China Nuokang Bio sees Baquting will perform during FY11 in line with FY10
Aug 25, 4:08PM FlyOnTheWall
Aug 25, 4:08PM FlyOnTheWall
China Nuokang Bio-Pharmaceutical Inc. Reports Second Quarter 2011 Financial Results
Aug 25, 4:01PM GlobeNewswire
Aug 25, 4:01PM GlobeNewswire
China Nuokang Bio-Pharmaceutical Inc. to Report Second Quarter 2011 Financial Results
Aug 17, 9:00AM GlobeNewswire
Aug 17, 9:00AM GlobeNewswire
China Nuokang Bio-Pharmaceutical Inc. Reports First Quarter 2011 Financial Results
May 25, 4:01PM GlobeNewswire
May 25, 4:01PM GlobeNewswire
China Nuokang Bio-Pharmaceutical Inc. to Report First Quarter 2011 Financial Results
May 12, 9:00AM GlobeNewswire
May 12, 9:00AM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NKBP | 4.50 | -0.16 | -3.43% | 89.66M |
| NKA | 11.67 | -0.28 | -2.34% | 412.16M |
| NJR | 41.80 | -0.82 | -1.92% | 1.768B |
| NGSX | 0.37 | +0.00 | +0.00% | 11.07M |
| NGPC | 6.71 | +0.03 | +0.45% | 144.49M |
| NGLS | 40.45 | -0.92 | -2.22% | 3.764B |
| NGG | 50.55 | -2.94 | -5.50% | 39.03B |
| NGB | 16.30 | +0.00 | +0.00% | |
| NFZ | 14.67 | +0.02 | +0.14% | |
| NFX | 30.56 | -1.58 | -4.92% | 4.346B |
